EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR

EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR

Allergic rhinitis (AR), the most prevalent immunological disease, affects approximately 400 million individuals globally and can significantly impact quality of life (QoL). Despite nearly 25 years of guidelines, AR remains largely under- diagnosed, suboptimally treated and poorly controlled. In the...

Full description

Saved in:
Bibliographic Details
Main Authors: G. K. Scadding, D. M. Conti, S. Scheire, V. Backer, M. Blaiss, L. O. Cardell, W. De Yun, A. K. Ellis, W. Fokkens, A. T. Fox, T. Gilbert Kruz, S. Halken, P. W. Hellings, V. Hox, L. Kalogjera, S. Lau, S. Marinho, M. McDonald, R. Mösges, J. Mullol, S. Nasser, R. Pawankar, D. Price, D. Ryan, G. Scadding, P. Smith, M. Sosa Kostrábová, M. Vazquez-Ortiz, U. Wahn, L. Zhang, P. Gevaert
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Allergy
Subjects:
allergic rhinitis
quality of life
definitions
severe allergic rhinoconjunctivitis (SARC)
refractory severe allergic rhinoconjunctivitis (R-SARC)
biologics
Online Access:https://www.frontiersin.org/articles/10.3389/falgy.2024.1531788/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Allergic rhinitis (AR), the most prevalent immunological disease, affects approximately 400 million individuals globally and can significantly impact quality of life (QoL). Despite nearly 25 years of guidelines, AR remains largely under- diagnosed, suboptimally treated and poorly controlled. In the light of new knowledge and treatment options, there is a necessity to update or revise fundamental AR definitions to facilitate communication across diverse specialties engaged in its treatment and to improve patient care. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) convened a meeting of experts and patient representatives to deliberate the optimal methodology for measuring AR treatment responses and establishing novel treatment goals. This paper presents a consensus on revised AR definitions, including control, severe allergic rhinoconjunctivitis (SARC), refractory severe allergic rhinoconjunctivitis (R-SARC), remission, resolution, improvement, exacerbation, treatable traits (TTs), treat to target, relapse, progression, disease modification, and prevention.
ISSN:2673-6101

Similar Items